For the acute treatment in cats a smaller bottle is required which contains enough of the pharmaceutical solution for the treatment of up to five (5) days. A container with approximately three (3) ml of an oral suspension comprising 0.5 mg/ ml meloxicam would fulfil these requirements. In addition such a composition would allow the treatment of several other species like small dogs (with a body weight of 0.5 kg up to 5 kg), rabbits and guinea pigs. Thus the problem underlying the present invention was to provide a plastic container containing a pharmaceutical composition comprising benzoic acid or a derivative thereof or a pharmaceutical acceptable salt thereof and a COX-inhibitor of the oxicam-type or a pharmaceutical acceptable salt thereof avoiding a significant loss of benzoic acid or a derivative thereof during storage. Furthermore, the problem underlying the present invention was to provide a plastic container containing a pharmaceutical composition comprising sodium benzoate and meloxicam avoiding a significant loss of sodium benzoate during storage.

BRIEF SUMMARY OF THE INVENTION

The present disclosure~~invention~~ relates to a plastic container containing a pharmaceutical composition comprising benzoic acid or a derivative thereof or a pharmaceutical acceptable salt thereof and a COX-inhibitor of the oxicam-type or a pharmaceutical acceptable salt thereof, wherein the container material is selected from one or more members of the group consisting of a homopolymer of polypropylene (PP), a copolymer of polypropylene (PP), a homopolymer of polyethylene terephthalate (PET) and a copolymer of polyethylene terephthalate (PET), and optionally non-polymeric components. In one aspect, there is provided a plastic container containing a pharmaceutical composition comprising sodium benzoate and meloxicam or a pharmaceutical acceptable salt thereof, characterised in that the container material is selected form one or more members of the group consisting of a homopolymer of polypropylene (PP), a copolymer of polypropylene (PP), a homopolymer of polyethylene terephthalate (PET) and a copolymer of polyethylene terephthalate (PET), and optionally one or more non-polymeric components. This container stores and/ or preserves a pharmaceutical composition comprising sodium benzoate and meloxicam or a pharmaceutical acceptable salt thereof, wherein the container material is constituted of polypropylene (PP) or polyethylene terephthalate (PET), i.e. the container material is selected from the group consisting of homopolymer of polypropylene (PP), copolymer of polypropylene (PP), homopolymer of polyethylene terephthalate (PET) and copolymer of polyethylene terephthalate (PET), and optionally non-polymeric components. The container also includes a closure device for storing and preserving a pharmaceutical composition, which can also be connected to a dispensing device.

The plastic container for storing, preserving and/ or dispensing a pharmaceutical composition comprising sodium benzoate and meloxicam or a pharmaceutical acceptable salt thereof has a volume of 3 to 11 ml with a total volume of the liquid composition of 2 ml to 10 ml.

The pharmaceutical composition that is stored and preserved within the bottle is a meloxicam-containing composition with meloxicam in a concentration of 0.2 mg/ ml to 20 mg/ ml. The pharmaceutical composition also comprises sodium benzoate in the concentration range of 0.8 mg/ ml to 2.0 mg/ ml.

Surprisingly the combination of the container according to the current disclosure~~invention~~ and the pharmaceutical composition comprising meloxicam and sodium benzoate enables the composition to remain substantially stable over 18 months or at least 18 months.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: PET Bottles – Sodium Benzoate Content over Storage Time
Figure 2: Glass Bottles – Sodium Benzoate Content over Storage Time
Figure 3: PC Bottles – Sodium Benzoate Content over Storage Time
Figure 4: PP Bottles – Sodium Benzoate Content over Storage Time
Figure 5: HDPE Bottle – Sodium Benzoate Content over Storage Time
Figure 6: LDPE Bottle – Sodium Benzoate Content over Storage Time
Figure 7: Storage at 25 °C / 60 % r.h. – Meloxicam Content for PP, HDPE and Glass Bottles (TW = Thin-walled HDPE bottles)
Figure 8: Dropper provided an integrated adaptor
Figure 9: Bottle - Plug-in device – Oral/ Dosing Syringe
Figure 10: Oral/ Dosing syringe

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a plastic container containing a pharmaceutical composition comprising benzoic acid, a derivative or pharmaceutically acceptable salt thereof and